REPL

Replimune Group Inc

The New York Times reported that Makary’s departure was driven in large part by his strong opposition to the administration’s decision to authorize fruit-flavored e-cigarettes.

The Wall Street Journal reported on the plans on Friday, citing people familiar with the matter, while noting that other top administration officials believe Makary is struggling to manage his agency.

FDA refused to approve Replimune’s melanoma drug RP1 for the second time in April, citing insufficient data to provide “substantial evidence of effectiveness” in the treatment of unresectable advanced cutaneous melanoma.

In trading on Monday, biotechnology shares were relative leaders, up on the day by about 2.1%. Leading the group were shares of Insight Molecular Diagnostics, up about 22.8% and shares of Replimune...

Replimune Group, Inc. (NASDAQ:REPL - Get Free Report) was the target of a large increase in short interest in April. As of April 15th, there was short interest totaling 18,426,035 shares, an increase...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc. - REPL INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of...

Wall Street Zen downgraded shares of Replimune Group from a "sell" rating to a "strong sell" rating in a research note on Saturday...

If you’re tired of getting sand kicked in your portfolio’s face, some of these stocks are hitting the gym and flexing. Not every stock here is ripped yet, but several are clearly bulking, a few are cutting into definition, and one or two might already be stepping on stage. $KBLB, $TZOO, $TRT, $AKAN, $TXN, $AUUD, $REPL

Doctors, in an opinion piece published on The Wall Street Journal, criticised the FDA’s decision, noting that the initial panel that reviewed RP1 recommended approval.